Clinical Trial Update: Primary Tumor Resection With EGFR TKI for Stage IV NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating primary tumor resection with an EGFR tyrosine kinase inhibitor for stage IV non-small cell lung cancer; the study is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR tyrosine kinase inhibitor (unspecified)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: NSCLC Stage IV | Phase 2 | Status: ACTIVE_NOT_RECRUITING